Clinical trial designs for rare diseases part 2 of 2, trial protocols /

Hämta fulltext

Surrogate endpoints, part 1 from definition to meta-analytic framework /

Hämta fulltext
Series

Surrogate endpoints, part 2 further developments /

Hämta fulltext
Series

Randomization, blinding and drug supply in interactive voice response trials

Hämta fulltext
Series

Phase II clinical trials traditional approaches /

Hämta fulltext
Series

Phase II clinical trials Bayesian methods /

Hämta fulltext
Series

Patient heterogeneity in dose-finding trials part 1, methods for 2 groups/

Hämta fulltext
Series

Patient heterogeneity in dose-finding trials part 2, more than 2 groups /

Hämta fulltext
Series

Implementation of adaptive methods in early phase clinical trials

Hämta fulltext
Series

Design and conduct of non-inferiority trials

Hämta fulltext
Series (Risk of bias in randomized clinical trials)
Series (Design and analysis of randomized clinical trials)

Adaptation in likelihood trials

Hämta fulltext
Series

The Salford lung study in COPD

Hämta fulltext
Series

Adaptive clinical trial design randomization /

Hämta fulltext
Series

Clinical research and care in the era of "N-of-1" precision cancer medicine

Hämta fulltext
Series

Frequentist approaches sample size in adaptive clinical designs /

Hämta fulltext
Series

Adaptive clinical trials overview, part 1 of 2 /

Hämta fulltext
Series

Adaptive clinical trials conclusion and future directions /

Hämta fulltext
Series

Adaptive clinical trials overview, part 2 of 2 /

Hämta fulltext
Series

Design early phase drug combination trials methods /

Hämta fulltext
Series

Design early phase drug combination trials software /

Hämta fulltext
Series